Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
회복기 혈장의 항체는 내인성 항체 반응이 있거나 없는 개인에서 SARS-CoV-2 제거를 촉진합니다
Clinical Trial
Published on
Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술,
Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술,
[키워드] 95% CI
absence
Adaptive immunity
adjusted hazard ratio
adverse events
affected
antibody
Antibody Response
clearance
Clinical research
Comorbidity
Comprehensive
conducted
convalescent plasma
Convalescent plasma therapy
Corona
COVID-19
Critical
demonstrated
disease status
Efficacy
evidenced
faster
hazard ratio
hospitalized COVID-19 patient
human infection
human infections
Immunotherapy
individual
Innovation
Intervention
IQR
Kaplan-Meier analysis
laboratory parameter
median interval
Mortality
neutralization
Neutralizing
neutralizing antibody
onset of symptom
parameter
Phase I
plasma
plasma therapy
pool
principle
priority
Program
promote
recipient
recipients
Red
respond
Safe
SARS-CoV-2
SARS-CoV-2 antibodies
SARS-CoV-2 clearance
SARS-CoV-2 vaccines
serological
significantly
survival
therapeutic
Therapeutics
therapy
transfusion-related adverse event
transfusion-related adverse events
Trial
university
University of Zurich
Viral
viral clearance
Viral load
Viremia
Virological
virus clearance
[DOI] 10.1172/JCI158190 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1172/JCI158190 PMC 바로가기 [Article Type] Clinical Trial